Immune Design Corp (IMDZ) Expected to Post Earnings of -$0.39 Per Share

Analysts forecast that Immune Design Corp (NASDAQ:IMDZ) will post earnings per share (EPS) of ($0.39) for the current quarter, Zacks reports. Two analysts have made estimates for Immune Design’s earnings. The lowest EPS estimate is ($0.46) and the highest is ($0.32). Immune Design posted earnings per share of ($0.57) during the same quarter last year, which would indicate a positive year over year growth rate of 31.6%. The company is scheduled to announce its next quarterly earnings report on Tuesday, March 6th.

On average, analysts expect that Immune Design will report full-year earnings of ($1.89) per share for the current financial year, with EPS estimates ranging from ($2.00) to ($1.76). For the next financial year, analysts forecast that the business will report earnings of ($1.40) per share, with EPS estimates ranging from ($1.58) to ($1.24). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Immune Design.

Immune Design (NASDAQ:IMDZ) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.11. Immune Design had a negative return on equity of 68.69% and a negative net margin of 619.62%. The business had revenue of $0.52 million during the quarter, compared to analyst estimates of $0.62 million.

IMDZ has been the subject of several research reports. Zacks Investment Research raised Immune Design from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a report on Monday, November 6th. Cowen reissued a “buy” rating on shares of Immune Design in a report on Monday, December 11th. Wells Fargo & Co lowered Immune Design from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $29.00 to $10.00 in a report on Tuesday, October 17th. Royal Bank of Canada began coverage on Immune Design in a report on Thursday, September 14th. They set an “outperform” rating and a $20.00 price objective for the company. Finally, ValuEngine downgraded Immune Design from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Immune Design currently has a consensus rating of “Buy” and an average target price of $13.06.

In related news, Director Franklin M. Berger bought 25,000 shares of the company’s stock in a transaction on Wednesday, October 25th. The shares were purchased at an average price of $4.26 per share, for a total transaction of $106,500.00. Following the completion of the transaction, the director now directly owns 50,000 shares in the company, valued at approximately $213,000. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Lewis W. Coleman bought 50,000 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were bought at an average price of $4.50 per share, for a total transaction of $225,000.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 5,290,000 shares of company stock worth $21,777,900. Company insiders own 20.70% of the company’s stock.

Several hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its position in shares of Immune Design by 9.3% in the second quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock worth $184,000 after buying an additional 1,600 shares in the last quarter. California State Teachers Retirement System raised its position in shares of Immune Design by 8.3% in the second quarter. California State Teachers Retirement System now owns 30,174 shares of the biotechnology company’s stock worth $294,000 after buying an additional 2,300 shares in the last quarter. Teachers Advisors LLC raised its position in shares of Immune Design by 23.0% in the second quarter. Teachers Advisors LLC now owns 27,691 shares of the biotechnology company’s stock worth $270,000 after buying an additional 5,181 shares in the last quarter. Rhumbline Advisers raised its position in shares of Immune Design by 53.9% in the second quarter. Rhumbline Advisers now owns 19,694 shares of the biotechnology company’s stock worth $192,000 after buying an additional 6,896 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of Immune Design by 123.3% in the first quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock worth $104,000 after buying an additional 8,418 shares in the last quarter. Institutional investors own 29.34% of the company’s stock.

Shares of Immune Design (IMDZ) traded down $0.15 during midday trading on Wednesday, reaching $3.95. The company’s stock had a trading volume of 375,719 shares, compared to its average volume of 440,250. Immune Design has a 1-year low of $3.50 and a 1-year high of $13.05. The company has a market capitalization of $194.64, a price-to-earnings ratio of -1.85 and a beta of 2.36.

COPYRIGHT VIOLATION WARNING: “Immune Design Corp (IMDZ) Expected to Post Earnings of -$0.39 Per Share” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/03/immune-design-corp-imdz-expected-to-post-earnings-of-0-39-per-share.html.

Immune Design Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Get a free copy of the Zacks research report on Immune Design (IMDZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immune Design (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply